| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
ORIGINAL RESEARCH |
From the Department of Obstetrics and Gynaecology, Liverpool Women’s Hospital, Liverpool, United Kingdom; Department of Obstetrics and Gynaecology, University of Liverpool, Liverpool Women’s Hospital, Liverpool, United Kingdom; and Department of Medicine and Therapeutics, University of Aberdeen Medical School, Aberdeen, United Kingdom.
Address reprint requests to: Roy G. Farquharson, MD, FRCOG, Liverpool Women’s Hospital, Department of Obstetrics and Gynaecology, Crown Street, Liverpool, L8 7SS, United Kingdom; E-mail: roy.farquharson{at}lwh-tr.nwest.nhs.uk.
OBJECTIVE: To compare the efficacy of low-dose aspirin alone versus low-dose aspirin plus low molecular weight heparin in pregnant women with antiphospholipid syndrome and recurrent miscarriage as prophylaxis against pregnancy loss.
METHODS: From a regional miscarriage clinic, 119 consecutive women with persistently positive tests for lupus anticoagulant and/or anticardiolipin immunoglobulin G and M antibody were invited to participate in a randomized, controlled trial between 1997 and 2000. After ethical approval and adherence to a written protocol, 12 women were unwilling to participate, five failed exclusion/inclusion criteria, and four were nonpregnant. Laboratory analysis was performed by Sheffield University Coagulation Department, electronically generated randomization by Manchester University Centre for Cancer Epidemiology, and data collection and analysis by a research officer at Leeds University. Viability ultrasound every 2 weeks was provided until 12 weeks’ gestation before transfer to the pregnancy support antenatal clinic.
RESULTS: Ninety-eight women were randomized before 12 weeks’ gestation. Forty-seven received low-dose aspirin 75 mg daily (group A), and 51 received low-dose aspirin plus low molecular weight heparin 5000 U subcutaneously daily (group B) throughout pregnancy. There were 13 pregnancy losses and 34 live births in group A and 11 losses and 40 live births in group B. The live-birth rate was 72% in group A and 78% in group B (odds ratio 1.39, 95% confidence interval 0.55, 3.47). There were no cases of maternal thrombosis in either group.
CONCLUSION: A high success rate is achieved when low-dose aspirin is used for antiphospholipid syndrome in pregnancy. The addition of low molecular weight heparin does not significantly improve pregnancy outcome.
This article has been cited by other articles:
|
|
 |
|
  M. Gayed and C. Gordon Pregnancy and rheumatic diseases Rheumatology, November 1, 2007; 46(11): 1634 - 1640. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Garcia, M. A. Khamashta, and M. A. Crowther How we diagnose and treat thrombotic manifestations of the antiphospholipid syndrome: a case-based review Blood, November 1, 2007; 110(9): 3122 - 3127. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Ganapathy, G. S. J. Whitley, J.E. Cartwright, P.R. Dash, and B. Thilaganathan Effect of heparin and fractionated heparin on trophoblast invasion Hum. Reprod., September 1, 2007; 22(9): 2523 - 2527. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. DE CAROLIS, A. BOTTA, S. GAROFALO, S. FERRAZZANI, C. MARTINO, G. FATIGANTE, L. CAFORIO, and A. CARUSO Uterine Artery Velocity Waveforms as Predictors of Pregnancy Outcome in Patients with Antiphospholipid Syndrome: A Review Ann. N.Y. Acad. Sci., June 1, 2007; 1108(1): 530 - 539. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Jauniaux, R. G. Farquharson, O. B. Christiansen, N. Exalto, and On behalf of ESHRE Special Interest Group for Earl Evidence-based guidelines for the investigation and medical treatment of recurrent miscarriage Hum. Reprod., September 1, 2006; 21(9): 2216 - 2222. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M L Bertolaccini and M A Khamashta Laboratory diagnosis and management challenges in the antiphospholipid syndrome Lupus, March 1, 2006; 15(3): 172 - 178. [Abstract] [PDF]
|
|
|
|
 |
|
 W. Lim, M. A. Crowther, and J. W. Eikelboom Management of Antiphospholipid Antibody Syndrome: A Systematic Review JAMA, March 1, 2006; 295(9): 1050 - 1057. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. B. Clowse, L. S. Magder, F. Witter, and M. Petri Early Risk Factors for Pregnancy Loss in Lupus Obstet. Gynecol., February 1, 2006; 107(2): 293 - 299. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. A. Greer and C. Nelson-Piercy Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy Blood, July 15, 2005; 106(2): 401 - 407. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. RUIZ-IRASTORZA and M. A. KHAMASHTA Management of Thrombosis in Antiphospholipid Syndrome and Systemic Lupus Erythematosus in Pregnancy Ann. N.Y. Acad. Sci., June 1, 2005; 1051(1): 606 - 612. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. M.H. Habayeb and J. C. Konje The one-stop recurrent miscarriage clinic: an evaluation of its effectiveness and outcome Hum. Reprod., December 1, 2004; 19(12): 2952 - 2958. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Bates, I. A. Greer, J. Hirsh, and J. S. Ginsberg Use of Antithrombotic Agents During Pregnancy: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 627S - 644S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Greaves Masterclass series in peripheral arterial disease: Acquired thrombophilia Vascular Medicine, August 1, 2004; 9(3): 215 - 218. [PDF]
|
|
|
|
 |
|
 M. A. Ozturk, I. C. Haznedaroglu, M. Turgut, and H. Goker Current Debates in Antiphospholipid Syndrome: The Acquired Antibody-Mediated Thrombophilia Clinical and Applied Thrombosis/Hemostasis, April 1, 2004; 10(2): 89 - 126. [Abstract] [PDF]
|
|
|
|
|
|
A Tincani, W Branch, R A Levy, J C Piette, H Carp, R S Rai, M Khamashta, and Y Shoenfeld Treatment of pregnant patients with antiphospholipid syndrome Lupus, July 1, 2003; 12(7): 524 - 529. [Abstract] [PDF]
|
|
|
|
|
|
D. W. Branch and M. A. Khamashta Antiphospholipid Syndrome: Obstetric Diagnosis, Management, and Controversies Obstet. Gynecol., June 1, 2003; 101(6): 1333 - 1344. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. D. Franklin and W. H. Kutteh Effects of Unfractionated and Low Molecular Weight Heparin on Antiphospholipid Antibody Binding In Vitro Obstet. Gynecol., March 1, 2003; 101(3): 455 - 462. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. von Dadelszen and N. Kent Antiphospholipid Syndrome in Pregnancy: A Randomized, Controlled Trial of Treatment Obstet. Gynecol., March 1, 2003; 101(3): 618 - 618. [Full Text] [PDF]
|
|
|
|
 |
|
 B. Jilma, S. Kamath, and G. Y H Lip ABC of antithrombotic therapy: Antithrombotic therapy in special circumstances. I---pregnancy and cancer BMJ, January 4, 2003; 326(7379): 37 - 40. [Full Text] [PDF]
|
|
|
|
|
|
R. Rai, L. Regan, W. H. Kutteh, R. G. Farquharson, S. M. Quenby, and M. Greaves Antiphospholipid Syndrome in Pregnancy: A Randomized, Controlled Trial of Treatment Obstet. Gynecol., December 1, 2002; 100(6): 1354 - 1356. [Full Text] [PDF]
|
|
|
|
 |
|
 Aspirin Is Effective Therapy for Antiphospholipid Syndrome in Pregnancy Journal Watch (General), September 17, 2002; 2002(917): 2 - 2. [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
